The nine B-ALL cases as well as four sporadic BL and one endemic BL were analyzed in this study, whereas the other BL cases were reviewed by Chapman et al.
The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis

TO THE EDITOR
Lymphoproliferative diseases, like acute leukemia (AL) in children, have potential to invade locally and infiltrate a variety of different tissues other than bone marrow, ie central nervous system or testis. The mechanisms of tumoral invasion involved in solid tumors are related to angiogenesis, endothelial adhesion and cell migration. Recent studies have hypothesized similar mechanisms for hemopathies, especially AL. 1 It has been suggested that angiogenesis could participate in AL cell proliferation, and therefore the secretion of modulators of angiogenesis such as bFGF has been considered as a possible indicator of the leukemic proliferation. The importance of angiogenic factors is not fully established. These angiogenic cytokines seem to be produced by leukemic and/or bone marrow (BM) microenvironmental cells. 2 Recently, Veiga et al 2 have shown a contact-dependent interaction between acute lymphoblastic leukaemia (ALL) cells of patients and BM endothelium in presence of angiogenic cytokines. This interaction leads to the survival of leukemic cells by maintaining the expression of anti-apoptotic genes. A recent study showed that high levels of cellular VEGF are significantly correlated with shorter survival in adult acute myeloblastic leukemia (AML) patients with high WBC at diagnosis (P Ͻ 0.04), whereas no association was found with the plasma levels of bFGF. 3 However, no correlation between angiogenesis and the prognosis of ALL has been described yet.
In a series of children with ALL, we found a correlation between usual poor prognostic features and the interactions between leukemic cells and BM microenvironment. Twenty-three newly diagnosed pro-B and pre-B-lineage ALL were studied for the urinary secretion of angiogenic cytokines (bFGF, VEGF). Diagnosis was established on BM aspirates and classification was made according to the usual immunophenotyping and cytogenetics. All children were treated according to the French protocol FRALLE 93. 4 The urinary bFGF and VEGF levels (pg/mmol creatinine/24 h) were determined by an ELISA method using the Quantikine FGF immunoassay (R&D Systems, Minneapolis, MN, USA) performed on a 24-h urine collection. For 11 patients, apoptosis of the leukemic cells was studied in the presence and the absence of an adherent monolayer of human embryonic fibroblast line (MRC5, Biomerieux, March-L'Etoile, France). Fibroblasts were cultured to confluence in RPMI 1640 and 15% FCS before the addition of leukemic cells in stem span serum-free medium (Stem Technologies, Meylan, France) (1 × 10 6 ALL cells/ml/well). Cocultures were carried out in triplicate, in 24-well plates, at 37°C with 5% CO 2 . The percentage of apoptotic cells was determined by flow cytometry (EPICS XL-MCL, Coulter, Margency) after 4 days of culture using the annexin V binding assay (Immunotech, Coulter Company, Marseilles, France).
The median urinary bFGF levels were significantly elevated in children with leukemia (15 months to 15 years old, median: 8) compared to the levels of 19 healthy controls under the age of puberty (3 to 13 years old, median: 10). At diagnosis the median values were significantly different (respectively 460 pg/mmol creatinine and 30 pg/mmol creatinine, P Ͻ 0.01) (Figure 1a) . A wide range was observed among our 23 patients at diagnosis, with bFGF levels from less than 0.25 to 29 837 pg/mmol creatinine. The normal value was 333 pg/ mmol creatinine of bFGF (mean + 2 s.d. of the control group). A large overlap between patients and controls was observed and 12 patients had normal values of bFGF. Eleven of them had very high risk leukemias, with adverse prognosis factors: five had a very high WBC at diagnosis (Ͼ50 × 10 9 /l), three a conserved hemoglobin level (Ͼ10 g/dl), one positive myeloid antigens (CD13, CD33), and two a resistance to initial treatment ( Table 1) . Most of these prognosis factors are associated with a high proliferation rate.
Among the 11 patients with an elevated level of bFGF (Ͼ333 pg/mmol creatinine), five patients had poor prognosis risk factors. These five patients did not have any special characteristics except elevated WBC or normal hemoglobin level. In the whole series there is a significant relationship between normal bFGF levels and high risk factors of ALL (Fisher exact test: P = 0.027). When considering the leukemic burden, no correlation was found between the WBC at presentation, the presence of a spleno-and/or hepatomegaly and the level of bFGF (data not shown).
Figure 1
Urinary levels of bFGF (a) and VEGF (b) in patients (P) and controls (C). (a) Median value of bFGF is significantly higher in ALL patients (n = 23) than in controls (n = 19): 460 vs 30, respectively (P Ͻ 0.01). (b) Median value of VEGF is higher in patients (n = 23) than in controls (n = 17) (42 vs 22), but the difference is not significant.
Urinary levels of VEGF were higher in ALL patients than in controls (n = 17) (median: 42 and 22 pg/mmol creatinine, respectively), but the difference is not significant (Figure 1b) . Eight children had high levels of VEGF as compared to the controls. Among the eight patients, two died and one relapsed. These three children had elevated WBC at diagnosis (100, 200 and 430 g/l) and VEGF level does not add any further information. No correlation was observed between VEGF and bFGF for each patient (data not shown).
We selected five patients with high levels of bFGF and six with normal levels. In the presence of fibroblasts, a significant reduction of apoptosis was observed in seven cases out of 11 (Ͼ50%, for patients with a spontaneous apoptosis rate Ͼ15%) (Figure 2 ). Fibroblasts seem to improve the cell survival of a subset of leukemia. Interestingly, the five patients with high levels of bFGF showed a significant reduction of apoptosis, however among the six patients with normal levels of bFGF, four showed no influence of fibroblasts on apoptosis. The four patients had adverse risk factors. This subset of leukemias seems to have growth independent of some of the components of the stroma.
Identifying prognostic features at diagnosis is essential to aim treatment intensity in ALL. Adverse evolution in AL can be related either to a high proliferative index of malignant cells or to their drug resistance, whatever the mechanism is. Normal hemoglobin level and high WBC at diagnosis are considered as relevant indicators of a high proliferation rate. It has been shown by Perez-Atayde et al 1 that childhood 
Figure 2
Spontaneous apoptosis of ALL cells in presence or absence of fibroblasts. In seven cases (7/11), there is a significant reduction of apoptosis when ALL cells are cultured with fibroblasts. On the contrary, four cases show no influence of fibroblasts on apoptosis. The Fisher exact test (P = 0.06) is not significant. A larger series is needed to show whether this trend can be confirmed.
ALL is associated with an increase of BM angiogenesis, as revealed by a significant increase of microvessel density on bone marrow biopsies. Increased angiogenesis in patients with AML has now been reported in several studies and is predictive of the patient's outcome. 3, 5 The importance of the stromal microenvironment in the proliferation of an AL is not clearly evaluated. Our hypothesis is that some high risk leukemias may proliferate without influence of the stromal microenvironment. On the contrary, the proliferation and probably the survival of most of the low risk common CD10 + lymphoblastic cells depends on the cell-to-cell interactions with the stromal cells. We studied two criteria: one probably associated with bone marrow angiogenesis, the bFGF; and the other related to the influence of the stromal microenvironment on cell apoptosis. 1 We found higher levels of angiogenic cytokines in only a subgroup of ALL patients. Patients could be discriminated according to their level of bFGF. Lower levels are clearly associated with a worse prognosis. However we could not establish a correlation between bFGF excretion and patient's outcome because of a too short follow-up time. It is too early to assume that bFGF could be an independent prognostic factor. Larger series are needed, but no previous study in ALL has been published regarding this association.
The production of angiogenic cytokines seems to depend on both leukemic and environmental cells. 6 In a recent study, Veiga et al 2 showed a contact-dependent interaction between leukemia cells and BM endothelium. This interaction leads to the prevention of apoptosis for ALL cells by maintaining the expression of anti-apoptotic genes. The same upregulation of bcl-2 expression has been reported in chronic lymphocytic leukemia cell lines and related to bFGF stimulation. 7 Without speculating about the underlying mechanisms, we showed that apoptosis was reduced in the presence of fibroblasts for all patients having high levels of bFGF. Interestingly, four out of six patients having normal levels of bFGF showed no influence of fibroblasts on apoptosis. These four patients have poor prognosis features associated with highly proliferative types of leukemia. We speculate that in these highly proliferative ALLs, the influence of the BM stroma and the secreted angiogenic factors can be overwhelmed and may be unnecessary for the development of the malignancy.
Concerning the initial resistance to treatment, an angiogenesis defect (with normal levels of angiogenic factors) could be responsible for a decreased chemotherapy diffusion in the BM. It has been shown recently that bFGF may protect hematopoietic tissue from irradiation, but little is known about its influence on the prevention of chemotherapy-induced damage. 8 Antiangiogenic therapy seems to be an innovative way to control tumor proliferation. Some angiogenic inhibitors are now submitted to clinical trials in solid tumors, but their place in the treatment strategy of high risk ALL needs to be assessed.
The bFGF may have origins from various sources, such as stromal cells, extracellular matrix, endothelium or leukemia cells. Further studies are underway in our group. However from present data, a high level of bFGF, whatever its source, seems to be the consequence rather than the origin of the stromal-dependence of some leukemias. 
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